. 2022 Nov 19;7:379. doi: 10.1038/s41392-022-01243-0

Table 2.

Summary of organelle-targeted cancer therapies under clinical trials

Drug name	Intervention mechanism	Cancer type	Clinical Trials.gov Identifier	Phase	Ref.
Elimusertib (BAY1895344)	ATR inhibition	Advanced solid tumors, lymphomas	NCT03188965	Phase 1
Elimusertib, Niraparib	ATR inhibition, PARP inhibition	Advanced solid tumors (excluding prostate cancer), ovarian cancer	NCT04267939	Phase 1
AZD6738	ATR inhibition	Solid tumor refractory to conventional treatment	NCT02223923	Phase 1
Veliparib, VX-970, Cisplatin	PARP inhibition, ATR inhibition	Neoplasms	NCT02723864	Phase 1
Azd6738, Olaparib	ATR inhibition, PARP inhibition	Gynecological cancers	Nct04065269	Phase 2
Atg-018	ATR inhibition	Advanced solid tumors, hematological malignancies	Nct05338346	Phase 1
Prexasertib (Ly2606368),	CHK1 inhibition	Advanced solid tumors	NCT02873975	Phase 2
Prexasertib (Ly2606368), Olaparib	CHK1 inhibition, PARP inhibition	Solid tumor	NCT03057145	Phase 1
LY2880070, Gemcitabine	CHK1 inhibition	Ewing sarcoma, Ewing-like sarcoma	NCT05275426	Phase 2
SRA737	CHK1 inhibition	Advanced solid tumors or non-Hodgkin’s lymphoma	NCT02797964	Phase 1 Phase 2
PHI-101	CHK2 inhibition	Platinum-resistant ovarian cancer, platinum-refractory ovarian carcinoma, platinum-resistant fallopian tube carcinoma, platinum-resistant primary peritoneal carcinoma	NCT04678102	Phase 1
Talazoparib (BMN 673)	PARP inhibition	Advanced ovarian cancer, primary peritoneal cancer, advanced breast cancer, advanced solid tumors	NCT01989546	Phase 1 Phase 2
Ceralasertib	DDR intervention	Head and neck squamous cell carcinoma	NCT03022409	Phase 1
Lmp400	DNA damage, delays DNA repair	Neoplasm, lymphoma	NCT01794104	Phase 1
Metformin	Metabolism disruption	Brain neoplasms	NCT02149459	Phase 1
Temozolomide	Metabolism disruption	Lung cancer	NCT00022711	Phase 2	⁴⁴⁰
Dichloroacetate (DCA)	Mitochondrial pyruvate dehydrogenase kinase inhibition	Malignant gliomas, glioblastoma multiforme	NCT00540176	Phase 2
Ketoconazole (Kcz) Posaconazole (Pcz)	HK2 inhibition	High-grade gliomas (WHO grade III and IV)	NCT03763396	Early Phase 1
ARQ 501	Redox homeostasis disruption	Head and neck neoplasms, carcinoma, squamous cell	NCT00358930	Phase 2	⁴⁴¹
Motexafin gadolinium	Redox homeostasis disruption	Renal cell carcinoma	NCT00134186	Phase 2	⁴⁴²
Pantoprazole	Proton pump inhibition	Advanced solid tumors	NCT01163903	Phase 1
Omeprazole	Proton pump inhibition	Breast cancer	NCT02595372	Phase 2
Lansoprazole	Proton pump inhibition	Breast cancer	NCT04874935	Phase 3
Bortezomib	Blocking the enzymes necessary for cancer cell growth	Recurrent breast cancer, stage IV breast cancer	NCT00025584	Phase 2
Nelfinavir	AKT signaling inhibition	Colorectal cancer	NCT00704600	Phase 2
Belinostat Atazanavir	Proteasome inhibitors	Hematological malignancies	NCT04184869	Phase 1

ATR Ataxia-telangiectasia and Rad3 related protein, CHK1 checkpoint kinase 1, DDR DNA damage response, PARP poly (ADP-ribose) polymerase, HK2 hexokinase 2